Evidence map›Paper›PMID 40874892›Full record

ArticleJACC. Basic to translational science2025

Novel Peptide Therapeutics Targeting the L-Type Calcium Channel Prevent Hypertrophic Cardiomyopathy by Decreasing Mitochondrial Energetics.

Teagan S Er, Daniel Reinke, Alice J Francis, Tanya M Solomon, Helena M Viola, Henrietta Cserne Szappanos, Caitlyn M Richworth, Catherine Jenkins, Juan E Camacho Londoño, Padmapriya Ponnuswamy and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Basic to translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Novel Drug Targets in Diastolic Heart Disease.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Teagan S ErSchool of Human Sciences (Physiology), The University of Western Australia, Crawley, Western Australia, Australia.
Daniel ReinkeSchool of Human Sciences (Physiology), The University of Western Australia, Crawley, Western Australia, Australia.
Alice J FrancisSchool of Human Sciences (Physiology), The University of Western Australia, Crawley, Western Australia, Australia.
Tanya M SolomonSchool of Human Sciences (Physiology), The University of Western Australia, Crawley, Western Australia, Australia.
Helena M ViolaSchool of Human Sciences (Physiology), The University of Western Australia, Crawley, Western Australia, Australia; Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia.
Henrietta Cserne SzappanosSchool of Human Sciences (Physiology), The University of Western Australia, Crawley, Western Australia, Australia.
Caitlyn M RichworthSchool of Human Sciences (Physiology), The University of Western Australia, Crawley, Western Australia, Australia.
Catherine JenkinsSchool of Human Sciences (Physiology), The University of Western Australia, Crawley, Western Australia, Australia.
Juan E Camacho LondoñoCSL Innovation GmbH, Marburg, Germany.
Padmapriya PonnuswamyCSL Innovation GmbH, Marburg, Germany.
Ciaran McFarlaneDepartment of Biochemistry and Molecular Biology, Life Sciences Institute (Faculty of Medicine), The University of British Columbia, Vancouver, British Columbia, Canada.
Filip Van PetegemDepartment of Biochemistry and Molecular Biology, Life Sciences Institute (Faculty of Medicine), The University of British Columbia, Vancouver, British Columbia, Canada.
Livia C HoolSchool of Human Sciences (Physiology), The University of Western Australia, Crawley, Western Australia, Australia; Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia. Electronic address: livia.hool@uwa.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondrial dysfunction is considered to drive the development of hypertrophic cardiomyopathy (HCM). In search of a preventative HCM therapy, we explored the efficacy of amino acid peptide variants that could alter the L-type Ca

Indexed as

cardiaccTnI-G203SmitochondriapreventionαMHC(403/+)

Identifiers

PMID40874892
PMCPMC12665424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.